Showing results (101-110 of 140) with videos related to
Sort By:
Pageof 14
Cancer Immunology, Immunotherapy : CII|December 29, 2018
Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancerAlberto A Chiappori, Charles C Williams, Jhanelle E Gray, et al.Leukemia Research|January 29, 2016
Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patientsNicholas J Achille, Megan Othus, Kathleen Phelan, et al.Oral Oncology|January 17, 2015
A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinomaJill Gilbert, Michael J Schell, Xiuhua Zhao, et al.Head & Neck|March 8, 2013
Intensity-modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinomaJames T May, Nikhil Rao, Roberto D Sabater, et al.Leukemia & Lymphoma|May 21, 2020
Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemiaEunice S Wang, Richard Aplenc, Deborah Chirnomas, et al.JTO Clinical and Research Reports|December 2, 2024
S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic CarcinomaAnne S Tsao, Ming-Hui Hsieh, Marianna Koczywas, et al.Oncotarget|January 1, 2017
Sensitizing leukemia stem cells to NF-κB inhibitor treatment in vivo by inactivation of both TNF and IL-1 signalingJing Li, Andrew Volk, Jun Zhang, et al.Blood|August 5, 2004
Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell linesChristiane Houde, Yulin Li, Lynda Song, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2013
Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancerGerold Bepler, Charles Williams, Michael J Schell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2014
A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumorsJhanelle E Gray, Eric Haura, Alberto Chiappori, et al.Pageof 14